Long‐term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices

Long‐term outcomes of apixaban as main anticoagulant in patients with HeartMate 3 left ventricular assist devices

Abstract Aims HeartMate 3 (HM3) left ventricular assist devices (LVADs) offer improved haemocompatibility‐related outcomes for end‐stage heart failure patients, facilitating the exploration of alternative anticoagulation therapies beyond warfarin. This study presents a long‐term evaluation of thromb...

Full description

Saved in:
Bibliographic Details
Main Authors: Jennifer Jdaidani, Mahmoud Shadi, Nnedi Asogwa, Jennifer Winik, Dora Rossi, Christina Saikus, Maria D. Avila, Geurys R. Rojas‐Marte
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:ESC Heart Failure
Subjects:
advanced heart failure
apixaban
HeartMate 3
left ventricular assist device
LVAD
warfarin
Online Access:https://doi.org/10.1002/ehf2.15182
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.15182

Similar Items